A role for P-glycoprotein in regulating cell death

Leukemia and Lymphoma

Volumn 38, Issue 1-2, 2000, Pages 1-11

  Johnstone, Ricky W ^a   Ruefli, Astrid A ^a   Tainton, Kellie M ^a   Smyth, Mark J ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Caspase; P glycoprotein; Pore formation

Indexed keywords

CHLORIDE CHANNEL; GLYCOPROTEIN P; XENOBIOTIC AGENT;

APOPTOSIS; CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL METABOLISM; DRUG TRANSPORT; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW;

EID: 0034007824     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009060314     Document Type: Review

References (81)

1. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987). Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA 84:3004-3008.
2. Gottesman MM, Pastan I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62:385-427.
3. Higgins CF and Gottesman MM (1997). Is the multidrug transporter a flippase? Trends Biochem. Sci. 17:18-21, 1997.
4. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. (1990). Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1277-1287.
5. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. (1994). P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451-2458.
6. Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM, Muller WA. (1998). A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. USA. 95:6924-6929.
7. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Borst P. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
8. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA. 94:4028-4033.
9. Panwala CM, Jones JC, Viney JL (1998). A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161:5733-5744.
10. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. (1992). Volume-regulated chloride channels associated with the human multidrug-resistance P-glycoprotein. Nature 355:830-833.
11. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepulveda FV. (1992). Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 71:23-32.
12. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda V, Higgins CF. (1995). Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J. 14:68-75.
13. Bond TD, Valverde MA, Higgins CF (1998). Protein kinase C phosphorylation disengages human and mouse-1a P-glycoproteins from influencing the rate of activation of swelling-activated chloride currents. J. Physiol. 508:333-340.
14. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. (1996). MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87:507-517.
15. Bosch I, Dunussi-Joannopoulos K, Wu RL, Furlong ST, Croop J. (1997). Phosphatidylcholine and phosphatidylethunolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 36:5685-5694.
16. Debry P, Nash EA, Neklason DW, Metherall JE. (1997). Role of Multidrug Resistance P-glycoproteins in Cholesterol Esterification. J. Biol. Chem. 272: 1026-1031.
17. Luker GD, Nilsson KR, Covey DF, Piwnica-Worms D. (1999). Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol. J. Biol. Chem. 274:6979-6991.
18. Raghu G, Park SW, Roninson IB, Mechetner EB. (1996). Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp. Hematol. 24:1258-1264.
19. Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M, Zojer N, Raderer M, Haberl I, Andreef M, Huber H. (1996). Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 88:1747-1754.
20. Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB, Roepe PD, Scheinberg DA. (1996). The multidrug resistance phenotype confers immunological resistance. J. Exp. Med. 183:2699-2704.
21. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD. (1997). Human MDR1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36:11169-11178.
22. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. (1998). The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA 95: 7024-7029.
23. Johnstone RW, Cretney E, Smyth MJ. (1999). P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-indepependent, cell death. Blood 93:1075-1085.
24. Geyp M, Ireland CM, Pittman SM. (1996). Resistance to apoptotic cell death in a drug resistant T cell leukaemia cell line. Leukemia 10:447-455.
25. Malorni W, Rainaldi G, Tritarelli E, Rivabene R, Cianfriglia M, Lehnert M, Donelli G, Peschele C, Testa U. (1996). Tumor necrosis factor alpha is a powerful apoptotic inducer in lymphoid leukemic cells expressing the P-170 glycoprotein. Int J Cancer 67:238-247.
26. Robinson LJ, Roepe PD (1996). Effects of membrane potential versus pHi on the cellular retention of doxorubicin analyzed via a comparison between cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance (MDR) transfectants. Biochem. Pharmacol. 52:1081-1095.
27. Roepe PD. (1995). The role of the MDR protein in altered drug translocation across tumor cell membranes. Biochim. Biophys. Acta. 1241:385-405.
28. Roepe PD, Wei LY, Cruz J, Carlson D. (1993). Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 32:11042-11056.
29. Hoffman MM, Wei LY, Roepe PD. (1996). Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance? J. Gen. Physiol. 108:295-313.
30. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP. (1998). Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J. 12:101-109.
31. Hoffman MM, Roepe PD. (1997). Analysis of ion transport perturbations caused by hu MDR 1 protein overexpression. Biochemistry 36:11153-68.
32. Hunnun YA (1997). Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845-1853.
33. Nagata S. (1997). Apoptosis by death factor. Cell 88:355-365.
34. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. (1997). Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90:3118-3129.
35. Friesen C, Herr I, Krammer PH, Debatin K-M (1996). Involvement of the CD95 (Apol/Fas) receptor/ligand system in drug-induced apoptosis in leukemia ells. Nat. Med. 2:574-577.
36. Fulda S, Los M, Friesen C, Debatin KM. (1997). Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer 76:105-114.
37. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SC (1997). Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90:935-943.
38. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. (1997). Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 57:3331-3334.
39. Walsh CM, Wen BG, Chinnaiyan AM, O'Rourke K, Dixit VM, Hedrick SM. (1998). A role for FADD in T cell activation and development. Immunity 8:439-449.
40. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. (1998). A dominant interfering mutant of FADD/MORT 1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17:706-718.
41. Miyashita T, Reed JC. (1993). Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157.
42. Schmitt E, Cimoli G, Steyaert A, Bertrand R. (1998). Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities. Exp. Cell. Res. 240:107-21.
43. Ruefli AA, Smyth MJ, Johnstone RW. (1999). HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein mediated multidrug resistance. Blood In press.
44. Enari M., Hug H. and Nagata S. (1995). Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78-81.
45. Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Droge W, Krammer PH, Fiers W, Schulze-Osthoff K. (1995). Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375:81-83.
46. Longthorne V.L. and Williams G.T. (1997). Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J. 16:3805-3812.
47. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Tijoe IM, Smith CA, Herzenberg LA, Herzenberg LA. (1997). Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J. Exp. Med. 186:1363-1372.
48. Vanags DM, Porn-Ares MI, Coppola S, Burgess DH, Orrenius S. (1997). Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J. Biol. Chem. 271:31075-31085.
49. Tewari M, Dixit VM. (1995). Fas-and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 270:3255-3260.
50. Beidler DR, Tewari M, Friesen PD, Poirier G, Dixit VM. (1995). The baculovirus p35 protein inhibits Fas-and tumor necrosis factor-induced apoptosis. J. Biol. Chem. 270:16526-16538.
51. Rehemtulla A, Hamilton CA, Chinnaiyan AR, Dixit VM. (1997). Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J. Biol. Chem. 272:25783-25786.
52. Los M, Wesselborg S, Schulze-Osthoff K. (1999). The role of caspases in development, immunity, and adaptor signal transduction: lessons from knockout mice. Immunity 10:629-639.
53. Ruefli AA, Tainton KM, Smyth MJ, Johnstone RW. (1999). Unpublished observations.
54. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA. (1997). Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. Am. J. Pathol. 151:1205-1213.
55. Trapani JA, Jans DA, Jans PJ, Smyth MJ, Browne KA, Sutton VR. (1998). Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J. Biol. Chem. 273:27934-27938.
56. Browne KA, Blink E, Sutton VR, Froelich CJ, Jans DA, Trapani JA. (1999). Bacterial toxins can replace perforin to facilitate cytosolic delivery of granzyme B: evidence that endosomal disruption is an important function of perforin, in addition to transmembrane pore-formation. Mol. Cell. Biol. In press.
57. Shinkai Y, Takio K, Okumura K. (1988). Homology of perforin to the ninth component of complement (C9). Nature 334:525-527.
58. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogolof H, Ervin T, Kufe D, Rifkind RA, Marks PA. (1992). Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemic: a phase II clinical trial with a differentiation-inducing agent. Blood 80:2604-2609.
59. Marks PA, Richon VM, Rifkind RA (1996). Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds. Int. J. Hematol. 63:1-17.
60. Siegel DS, Zhang X, Feinman R, Teitz T, Zelenetz A, Richon VM, Rifkind RA, Marks P A, Michaeli J. (1998). Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells. Proc Natl Acad Sci USA 95:162.
61. Trapani JA, Sutton VR. Smyth MJ (1999). CTL granules: evolution of vesicles essential for combating virus infections. Immunol. Today 20:351-356.
62. Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC (1998). E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk, J. Cell. Biol. 140:637-644.
63. Deas O, Dumont C, MacFarlane M, Rouleau M, Hebib C, Harper F, Hirsch F, Charpentier B, Cohen G M, Senik A. (1997). Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes. J Immunol. J Immunology 161:3375-3380.
64. De Maria R, Lenti L, Malisan F, d'Agostin F, Tomassini B, Zeuner A, Rippo MR, Testi R (1997). Requirement for the GD3 ganglioside in CD95-and ceramide-induced apoptosis. Science 277:1652-1655.
65. Bossy-Wetzel E, Newmeyer DD, Green DR. (1998). Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J. 17:37-43.
66. Miller TM, Moulder KL, Knudson CM, Creedon DJ, Deshmukh M, Korsmeyer SJ, Johnson EM, Jr. (1997). Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J. Cell. Biol. 139:205-210.
67. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. (1996). FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817-827.
68. +-ATPase. Proc. Natl. Acad. Sci. USA 92:5965-5968.
69. Furlong IJ, Ascaso R, Rivas AL, Collins MKL. (1997). Intracellular acidification induces apoptosis by stimulating ICE-like protease activity. J. Cell. Sci. 110:653-661.
70. Stennicke HR, Salvesen GS. (1997) Biochemical characteristics of caspases-3, -6, -7, and -8. J. Biol. Chem. 272:25719-25723.
71. Garcia-Calvo M, Peterson EP, Rasper DM, Vaillancourt JP, Zamboni R, Nicholson DW, Thornberry NA. (1999). Purification and catalytic properties of human caspase family members. Cell. Death. Differ. 6:362-369.
72. Gottlieb RA, Nordberg J, Skowronski E, Babior BM. (1996). Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc. Natl. Acad. Sci. USA 93:654-658.
73. Weisburg JH, Roepe PD, Dzekunov S, Scheinberg DA. (1999). Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J. Biol. Chem. 274:10877-10888.
74. Dalmasso AP, Lelchuk R, Giavedoni EB, De Isola ED. (1975). The modifications of the final stages of the complement reaction by alkali metal cations. J. Immunol. 115:63-68.
75. Alouf JE, Geoffroy C, Pattus F, Verger R. (1984). Surface properties of bacterial sulfhydryl-activated cytolytic toxins. Interaction with monomolecular films of phosphatidylcholine and various sterols. Eur. J. Biochem. 141:205-210.
76. Young JD, Damiano A, DiNome MA, Leong LG, Cohn ZA. (1987). Dissociation of membrane binding and lytic activites of the lymphocyte pore-forming protein (perforin). J. Exp. Med. 165:1371-1382.
77. Esser AF, Kolb WP, Podack ER, Muller-Eberhard HJ. (1979). Molecular reorganization of lipid bilayers by complement: a possible mechanism for membranołysis. Proc. Natl. Acad. Sci. USA 76:1410-1414.
78. Anita R, Schlegal RA, Williamson P. (1992). Binding of perforin to membranes is sensitive to lipid spacing but not head-groups. Immunol. Letts. 32:153-158.
79. Uellner R, Zvelebil MJ, Hopkins J, Jones J, MacDougall LK, Morgan BP, Podack E, Waterfield MD, Griffiths GM. (1997) Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J. 16:7287-7296.
80. Bunting KD, Galipeau J, Topham D, Benaim E, Sorrentino BP. (1998). Transduction of bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92:2269-2279.
81. Ruetz S, Gros P. (1994). Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell. 77:1071-81.